Parallel Advisors LLC Raises Stake in GRAIL, Inc. $GRAL

Parallel Advisors LLC increased its stake in shares of GRAIL, Inc. (NASDAQ:GRAL) by 24.1% during the second quarter, according to its most recent filing with the SEC. The institutional investor owned 2,313 shares of the company’s stock after purchasing an additional 449 shares during the period. Parallel Advisors LLC’s holdings in GRAIL were worth $119,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Wesbanco Bank Inc. grew its holdings in shares of GRAIL by 39.1% during the second quarter. Wesbanco Bank Inc. now owns 44,500 shares of the company’s stock worth $2,288,000 after purchasing an additional 12,500 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in shares of GRAIL by 37.4% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 92,465 shares of the company’s stock worth $2,362,000 after purchasing an additional 25,177 shares in the last quarter. Scientech Research LLC purchased a new position in shares of GRAIL during the first quarter worth about $644,000. NewEdge Advisors LLC grew its holdings in shares of GRAIL by 390.3% during the first quarter. NewEdge Advisors LLC now owns 1,760 shares of the company’s stock worth $45,000 after purchasing an additional 1,401 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of GRAIL by 28.2% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 2,835 shares of the company’s stock worth $76,000 after purchasing an additional 623 shares in the last quarter.

GRAIL Trading Up 5.6%

Shares of NASDAQ GRAL opened at $46.98 on Wednesday. GRAIL, Inc. has a 12 month low of $12.33 and a 12 month high of $63.99. The firm has a market capitalization of $1.69 billion, a price-to-earnings ratio of -3.58 and a beta of 3.18. The business has a 50-day moving average of $35.59 and a 200-day moving average of $35.66.

GRAIL (NASDAQ:GRAL) last issued its quarterly earnings data on Tuesday, August 12th. The company reported ($3.18) EPS for the quarter, missing the consensus estimate of ($3.14) by ($0.04). The business had revenue of $35.54 million for the quarter, compared to analysts’ expectations of $37.57 million. GRAIL had a negative return on equity of 16.64% and a negative net margin of 329.86%. On average, analysts predict that GRAIL, Inc. will post -15.15 earnings per share for the current year.

Insider Activity

In other news, President Joshua J. Ofman sold 9,692 shares of the stock in a transaction dated Monday, June 30th. The stock was sold at an average price of $52.00, for a total transaction of $503,984.00. Following the transaction, the president directly owned 492,076 shares in the company, valued at approximately $25,587,952. This represents a 1.93% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Aaron Freidin sold 8,000 shares of the stock in a transaction dated Tuesday, July 15th. The shares were sold at an average price of $38.93, for a total value of $311,440.00. Following the transaction, the chief financial officer owned 286,020 shares in the company, valued at $11,134,758.60. This trade represents a 2.72% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 361,694 shares of company stock worth $17,780,266.

GRAIL Company Profile

GRAIL, Inc operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T.